Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feladilimab plus Docetaxel in NSCLC
NCT05553808Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2019
- Primary completion
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of feladilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by GSK. Primary endpoint: Overall Survival at 2 years. Started Jan 2019; status: completed.
02
Drugs
feladilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05553808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05553808.